ImmunoGen, OraVax deal

ORVX purchased IMGN's 47,000 square foot Canton, Mass., manufacturing facility for $2.3 million. The facility will handle commercial production of HNK20, ORVX's monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infections and viral pneumonia. HNK20 is in Phase II trials. ...